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Insulin-like growth factor-I (IGF-I) is a peptide with both mito-
genic and anti-apoptopic properties. Unlike other growth factors, it
has characteristics of both a tissue growth factor and an endocrine
hormone (Jones and Clemmons, 1995; Rajaram et al, 1997).
Circulating IGF-I levels are subject to complex physiological
regulation, and vary considerably between normal individuals
(Harrela et al, 1996). Most circulating IGF-I originates in the liver,
and growth hormone is a key up-regulator of hepatic IGF-I
production. IGF bioactivity in tissues is not merely a function of
circulating concentration; local expression of IGFs, IGF-binding
proteins, and proteases that digest IGF-binding proteins are also
important factors. Clinical and experimental evidence suggesting
important roles of IGF physiology in carcinogenesis and
neoplastic progression have been the subject of recent reviews
(Burroughs et al, 1999; Khandwala et al, 2000; Pollak, 2000). 
Several epidemiological studies provide evidence that circu-
lating IGF-I level is related to breast cancer risk among
premenopausal women (Peyrat et al, 1993; Bruning et al, 1995;
Bohlke et al, 1998; Hankinson et al, 1998; Toniolo et al, 2000; Li
et al, 2001). A recent report (Byrne et al, 2000) provides evidence
that circulating IGF-I level is highly correlated with mammo-
graphic density, which has previously been shown to be related to
breast cancer risk. Separate data also suggest a relationship
between circulating IGF-I level and risk of other cancers
(Barinaga, 1998; Chan et al, 1998; Maison et al, 1998; Wolk 
et al, 1998; Burroughs et al, 1999; Holly et al, 1999; Manousos 
et al, 1999; Yu et al, 1999; Holly and Smith, 2000; Shaneyfelt et al,
2000). The mechanism underlying the IGF-I-cancer risk relation-
ship remains unclear, but may relate to increased epithelial cell
turnover and/or increased cell survival in individuals with higher
IGF-I tissue bioactivity (Cohen and Ellwein, 1990; Ng et al, 1997;
Pollak et al, 1999; Pollak, 2000). 
Separate research has provided evidence that body size or
weight early in life is positively correlated with subsequent risk of
breast cancer (Michels et al, 1996; Stavola et al, 2000; Kaijser 
et al, 2001). The biological basis for this observation has been the
subject of considerable speculation (for example, Vatten, 1996;
Stoll, 1997; Signorello and Trichopoulos, 1998) but has not been
addressed in experimental work. In view of evidence that body
size early in life is related to cord blood IGF-I level (Ong et al,
2000), we hypothesized that the reason that there is a relation
between body size early in life and subsequent breast cancer risk is
that both are influenced by IGF-I levels. IGF-I levels are known to
vary substantially between normal individuals, and approximately
50% of this variation is attributable to genetic factors which have
not yet been characterized (Harrela et al, 1996). To address this
hypothesis, we studied the effect of experimental perturbation of
the GH-IGF-I axis in a transgenic mouse model on experimental
mammary gland carcinogenesis. 
Transgenic mice that constitutively express a bovine (Chen 
et al, 1990, 1991) or human (Chen et al, 1994) GH antagonist have
been produced. In the present study, we examined tumour inci-
dence in GH antagonist transgenic (GHA-tg) mice and in non-
transgenic littermates in the standard dimethylbenz[a]anthracene
(DMBA) breast carcinogenesis model in order to determine if an
intervention targeted specifically at the GH–IGF-I axis would
influence breast carcinogenesis. 
28 8-week-old female GHA-tg mice (Chen et al, 1990) and 26
control littermates of the same age were given, by gavage, DMBA
(70 mg g–1 body weight) resuspended in peanut oil. The gavages
were administrated once a week for 6 weeks. After the last gavage,
tumour appearance was monitored weekly and tumours were
measured with a calipre. Mice with tumours were sacrificed when
tumours reached~1 cm in diameter or 39 weeks after DMBA treat-
ment. The mice were weighed, measured and blood was collected
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subsequently assayed using an ELISA for rodent IGF-I (reagents
from Diagnostic System Limited, Webster, Texas). Mice were
handled in accordance with a protocol approved by McGill
University and Lady Davis Institute animal care committees, and
in accordance with the UKCCCR guidelines, and were maintained
in a temperature-controlled environment with diurnal cycle of 12
hours of light and 12 hours of darkness, on an ad libitum diet
(UKCCCR, 1998). Statistical tests (Student’s t-test) were two-
sided;  P values of <0.05 were considered to be significant. 
The GHA-tg mice had lower levels of circulating IGF-I than
control littermates (Table 1). GHA-tg mice were significantly
smaller and lighter than non-transgenic animals, as previously
reported (Chen et al, 1990). The GHA-tg female mice had grossly
normal mammary glands, and normal ductal and stromal architec-
ture on routine microscopy. Lactational performance of these mice
was normal. 
Tumour incidence was substantially reduced in GHA-tg mice
compared to control mice (Table 1, Figure 1). The difference
between the tumour incidence curves was highly significant
(P <0.001). The tumours were breast adenocarcinomas, as previ-
ously reported with the DMBA model (Russo and Russo, 1996). 
Epidemiological studies have provided evidence that individ-
uals with circulating IGF-I levels at the high end of the normal
range have higher risk for premenopausal breast cancer than indi-
viduals with IGF-I levels at the low end of the normal range
(Peyrat et al, 1993; Bruning et al, 1995; Bohlke et al, 1998;
Hankinson et al, 1998; Toniolo et al, 2000; Li et al, 2001). 
Separate evidence suggests that body size and weight early in
life are related to subsequent breast cancer risk (Michels et al,
1996; Stavola et al, 2000; Kaijser et al, 2001). We show in a trans-
genic model that the phenotype associated with expression of a
GH antagonist includes not only reduced body size and reduced
circulating IGF-I level, but also reduced susceptibility to DMBA-
induced mammary gland carcinogenesis. This suggests that inter-
individual variations in the GH–IGF-I axis have important
influences on both birthweight and breast cancer risk, and thus
may explain at least in part the association between birthweight
and breast cancer risk. 
Our study design does not allow us to determine if there is a crit-
ical time at which IGF-I levels influence risk. It is known that a
significant component of the inter-individual variation in IGF-I
levels is genetically determined (Harrela et al, 1996), and it is
possible that the influence of IGF-I on cancer risk operates through
effects on epithelial cell renewal dynamics throughout life,
including prenatal life, the period of pubertal breast development,
and young adulthood. 
The recent description of the safety and IGF-I lowering action
of a GH antagonist in acromegalics (Trainer et al, 2000), together
with our experimental results, raise the possibility that targeting
the GH–IGF-I axis may represent a novel approach for cancer risk
reduction for individuals with IGF-I levels at the high end of the
normal range. This would be particularly relevant to the challenge
of risk reduction for individuals who have known cancer risk
factors such as carcinogen exposure, a germ line mutation in a
cancer predisposition gene, or mutagen sensitivity, whose risk may
be amplified by high IGF-I levels (Wu et al, 2000). It remains to be
determined, however, if reduction of IGF-I levels from the high to
the low end of the normal range in adulthood would in fact reduce
IGF-I related cancer risk. It is conceivable that IGF-I levels in
middle age are related to cancer risk only because they represent a
surrogate for levels at some early critical period, such as puberty,
at which time they influence risk. If this is the case, then interven-
tions later in life will have little effect. Animal models of this issue
are difficult due to species differences in growth, development
and puberty. Nevertheless, early work involving perturbation of
the GH–IGF-I axis with somatostatin analogues subsequent to
carcinogen exposure in murine mammary carcinogenesis systems
(Pollak and Schally, 1998) does provide evidence for reduction
mammary cancer incidence even if treatment is deferred and
should provide a foundation for further research. 
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Table 1 Characteristics of control and growth hormone antagonist transgenic mice 
Body length (cm) Body weight (g) Circulating IGF-I concentration Percentage without 
(ng ml–1) tumour  at 39 weeks (%) 
Control mice 9.5 ± 0.5 31.0 ± 2.6 186.9 ± 8.8 31.6 
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P value <0.005 <0.0001 <0.0001 < 0.001 
The results are expressed as the mean ± SEM. 
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Figure 1 Tumour incidence in growth hormone antagonist (GHA) transgenic
mice vs. control mice following DMBA exposure. During the 39 weeks
following DMBA treatment, tumour appearance was monitored as described
in the text. 430 M Pollak et al 
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